Tags Archives: impella

Perfusfind S.L.

Abstract Background Hemolysis, variably defined in mechanical circulatory support (MCS), is understudied in percutaneous left ventricular assist devices. We characterize hemolytic sequelae of Impella 5.5-supported patients in the largest series..

Perfusfind S.L.

Abstract Purpose Venoarterial extracorporeal membrane oxygenation (VA ECMO) is used in patients with refractory cardiac or cardio-pulmonary failure. Native ventricular output interacts with VA ECMO flow and may hinder sufficient..

Perfusfind S.L.

Abstract Objective: Impella 5.5 (Abiomed, Danvers, MA, USA) is a temporary mechanical circulatory support device used for patients in cardiogenic shock. This review provides a comprehensive overview of the device’s..

Perfusfind S.L.

Abstract Mechanical circulatory support (MCS) plays a significant role as a therapeutic option for severe heart failure, and its outcomes have been improving due to advancements in devices and management..

Perfusfind S.L.

Watch the panel discussion and three case presentations during our next Global Grand Rounds webinar this Wednesday at 8am ET. Register for the replay:

Perfusfind S.L.

Abstract This case report explores the successful use of the Impella 5.5 (Abiomed Inc., Danvers, MA) device in a 22 kg, 0.89 body surface area (BSA) pediatric patient with longstanding dilated..

Perfusfind S.L.

Abstract Purpose of review  This article offers an overview of recent randomized controlled trials (RCTs) testing the efficacy of veno-arterial extracorporeal membrane oxygenation (VA ECMO) and microaxial flow pump (mAFP)..

Perfusfind S.L.

Abstract Mortality in infarct-related as well as heart failure-associated cardiogenic shock remains high, reaching 40–50% depending on the etiology and severity of cardiogenic shock. Percutaneous active mechanical circulatory support devices..

Perfusfind S.L.

Abstract Background: Cardiogenic shock in children still carries a high mortality risk despite advances in medical therapy. The use of temporary mechanical circulatory supports is an accepted strategy to bridge patients..

Perfusfind S.L.

Abstract Left ventricular (LV) unloading has been shown to improve survival for patients requiring veno-arterial extracorporeal membrane oxygenation (VA ECMO) support for cardiogenic shock. A mortality benefit has been shown..

Perfusfind S.L.

Abstract Objectives:  Extracorporeal cardiopulmonary resuscitation (ECPR) is the implementation of venoarterial extracorporeal membrane oxygenation (VA-ECMO) during refractory cardiac arrest. The role of left-ventricular (LV) unloading with Impella in addition to..

Perfusfind S.L.

Abstract Venoarterial extracorporeal membrane oxygenation (VA-ECMO) use for circulatory support in cardiogenic shock results in increased left ventricular (LV) afterload. The use of concomitant Impella or intra-aortic balloon pump (IABP)..

Perfusfind S.L.

Abstract Primary graft dysfunction is a feared complication and cause of mortality post–heart transplant. Primary graft dysfunction may require mechanical circulatory support, such as venoarterial extracorporeal membrane oxygenation, which carries..

Perfusfind S.L.

Abstract Summary The importance of temporary mechanical circulatory support for treating acute heart failure with cardiogenic shock is increasingly recognized, and Impella (Abiomed, Danvers, MA, USA) has received particular attention..

Perfusfind S.L.

Abstract Background: Although extracorporeal membrane oxygenation (ECMO) is an integral part of a robust cardiogenic shock program, it is associated with high mortality. The optimal strategy for weaning from ECMO is..

Perfusfind S.L.

Abstract We sought to remedy the limited guidance that is available to support the resuscitation of patients with the Impella Cardiac Power (CP) and 5.0 devices during episodes of cardiac..

Perfusfind S.L.

Abstract This article describes a case study where a patient with ProtekDuo + oxygenator and Impella CP (PROpella) in biventricular failure and cardiogenic shock was reconfigured to venopulmonary-arterial (VP-A) extracorporeal..

Perfusfind S.L.

Abstract Objectives Placement of the Impella 5.0 percutaneous left ventricular assist device may cause aortic regurgitation (AR) due to malcoaptation of the aortic leaflets. The authors investigated the prevalence and..

Perfusfind S.L.

Abstract Introduction: Use of the ProtekDuo cannula has been described for right ventricular assist devices (RVADs) and extracorporeal membrane oxygenation (ECMO) systems. Case report: We describe remote cannulation and transport of two..

Perfusfind S.L.

Abstract Danvers, Mass., October 21, 2022 –  (Nasdaq: ABMD) announces the U.S. Food and Drug Administration (FDA) has accepted and closed the post-approval study reports related to the pre-market approvals (PMA)..

Perfusfind S.L.

  Jörn Tongers, MD, discusses his recently published paper evaluating the efficacy and safety of early combined mechanical circulatory support (MCS) with an Impella® heart pump and venoarterial extracorporeal membrane..

Perfusfind S.L.

Abstract Background Despite many reports of clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (HRPCI) with hemodynamic support, little is known about whether this approach improves left ventricular ejection..

Perfusfind S.L.

Abstract Prolonged mechanical circulatory support (MCS) for severe left ventricular dysfunction in cardiogenic shock as a bridge to heart transplantation (HTx) generally requires a surgical procedure. Typically, a surgically implanted..

Perfusfind S.L.

Abstract In patients with severe cardiogenic shock, temporary mechanical circulatory support has become a viable strategy to bridge patients to heart transplantation. However, end-stage heart failure is often associated with progressive organ..

Perfusfind S.L.

Abstract Background: With the rapid development of mechanical circulatory support technologies, patients presenting with cardiogenic shock have gained access to various treatment opportunities which were not until recently available. The Impella®..

Perfusfind S.L.

Abstract The Impella CP (Abiomed Inc., Danvers, MA) is widely used in cardiac catheterization laboratories for patients presenting with cardiogenic shock, but it is also known to cause significant hemolysis. The risk..

Perfusfind S.L.

EuroELSO Webinar on March 03, 2022 Combined ECLS with ECMO and Impella indications, physiological basis and management"Topic: "Combined ECLS with ECMO and Impella indications, physiological basis and management"Presentation: Clara Hernandez CaballeroModeration:..

Perfusfind S.L.

Abstract The Impella mechanical circulatory support (MCS) system is a catheter-based continuous flow cardiac assist device that is widely used in the treatment of cardiogenic shock in medical and surgical cardiac intensive..

Perfusfind S.L.

Abstract Peripheral venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute cardiac failure reestablishes normal oxygen delivery and perfusion. However, VA ECMO can be limited by insufficient ventricular unloading, resulting in..

Perfusfind S.L.

Abstract Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is used as mechanical circulatory support in cardiogenic shock (CS). It restores peripheral perfusion, at the expense of increased left ventricle (LV) afterload. In..